Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:PEN News 15 January 2026 - 30 January 2026

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific shares rose 1.7% to $93.87 Friday afternoon, outpacing a broader market decline. The move comes ahead of the company’s Feb. 4 earnings report and conference call, its first since announcing a $14.5 billion deal to acquire Penumbra. Investors are watching for details on the acquisition’s impact and the 2026 outlook.
30 January 2026
···
Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific shares fell 1.8% to $88.44 Friday after its $14.5 billion deal to buy Penumbra, while Penumbra rose 0.3% to $351.62. Boston will fund most of the purchase with cash and new debt, expecting a $0.06–$0.08 hit to adjusted EPS in the first year. Penumbra shareholders can choose cash or Boston stock. Deal filings and Boston’s earnings call are set for February 4.
16 January 2026
··
Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra shares jumped 11.8% to $350.49 in after-hours trading Thursday after Boston Scientific announced a $14.5 billion cash-and-stock acquisition valuing Penumbra at $374 per share. The deal requires Penumbra shareholder approval and antitrust clearance. Penumbra posted preliminary Q4 revenue growth of over 21% year-over-year. Traders focused on the deal spread and closing risks.
15 January 2026
··
Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open

Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open

Boston Scientific will acquire Penumbra for about $14.5 billion, offering $374 per share in cash and stock. Penumbra shares rose more than 13% premarket, with the bid representing a 19.3% premium to the previous close. The deal expands Boston Scientific’s reach in catheter-based clot removal and neurovascular devices. Penumbra CEO Adam Elsesser will join Boston Scientific’s board.
15 January 2026
··

Stock Market Today

Alphabet stock drops for a fourth straight day as AI spending jitters linger

Alphabet stock drops for a fourth straight day as AI spending jitters linger

7 February 2026
Alphabet shares fell 2.53% to $322.86 Friday, marking a fourth straight decline as investors questioned heavy AI-related spending. The Nasdaq slipped Thursday after Alphabet detailed up to $185 billion in capex, while the Dow and S&P 500 rose Friday on chipmaker gains. U.S. markets reopen Monday, with attention on Alphabet’s outlook and upcoming jobs and inflation data.
BBAI stock jumps 16% into BigBear.ai share-vote week — what to watch next

BBAI stock jumps 16% into BigBear.ai share-vote week — what to watch next

7 February 2026
BigBear.ai Holdings shares surged 15.7% Friday to $4.72 ahead of a key shareholder vote on doubling authorized shares to 1 billion. Options trading was heavy, with a put/call ratio of 0.19. The company recently announced deals in AI customs technology and a partnership with Abu Dhabi’s AD Ports Group. The special meeting is set for Feb. 18, with online voting open until late Feb. 17.
Go toTop